1.66 J&J to buy targeted cancer therapy developer Ambrx for $2 billion

News


<< back

J&J to buy targeted cancer therapy developer Ambrx for $2 billion
Date: 2024-01-08 [news.yahoo.com]

READ THE FULL NEWS >>
×